| UTHEALTH HOME ABOUT SBMI A-Z WEBMAIL INSIDE THE UNIVERSITY |
|
|||||||
|
Kinase Fusion Gene:CLK1_ORC2 |
Kinase Fusion Protein Summary |
 Kinase Fusion gene summary |
| Kinase Fusion partner gene information | Kinase Fusion gene name: CLK1_ORC2 | KinaseFusionDB ID: KFG1328 | FusionGDB2.0 ID: KFG1328 | Hgene | Tgene | Gene symbol | CLK1 | ORC2 | Gene ID | 78989 | 83884 | |
| Gene name | ||||||||||||
| Synonyms | ||||||||||||
| Cytomap | ||||||||||||
| Type of gene | ||||||||||||
| Description | ||||||||||||
| Modification date | ||||||||||||
| UniProtAcc | P49759 | Q9BXI2 | ||||||||||
| Ensembl transtripts involved in fusion gene | ENST ids | ENST00000321356, ENST00000492793, ENST00000409769, ENST00000434813, | ENST00000234296, ENST00000467605, | |||||||||
| Context (manual curation of fusion genes in KinaseFusionDB) | PubMed: CLK1 [Title/Abstract] AND ORC2 [Title/Abstract] AND fusion [Title/Abstract] | |||||||||||
| Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0) | CLK1(201729287)-ORC2(201778715), # samples:2 | |||||||||||
| Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
| Partner | Gene | GO ID | GO term | PubMed ID |
| Kinase Fusion gene breakpoints across CLK1 (5'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
| Kinase Fusion gene breakpoints across ORC2 (3'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
Top |
Kinase Fusion Gene Sample Information |
| Kinase Fusion gene information. |
| Kinase Fusion gene information from four resources (ChiTars 5.0, ChimerDB 4.0, COSMIC, and CCLE) * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| Source | Sample | Hgene | Hchr | Hbp | Tgene | Tchr | Tbp |
| ChimerDB4 | TCGA-D7-6527-01A | CLK1 | chr2 | 201729287 | ORC2 | chr2 | 201778715 |
| ChimerDB4 | TCGA-D7-6527 | CLK1 | chr2 | 201729286 | ORC2 | chr2 | 201778715 |
Top |
Kinase Fusion ORF Analysis |
| Kinase Fusion information from ORFfinder translation from full-length transcript sequence from KinaseFusionDB. |
| Henst | Tenst | Hgene | Hchr | Hbp | Tgene | Tchr | Tbp | Seq length (transcript) | Seq length (amino acids) |
Top |
Kinase Fusion Amino Acid Sequences |
| For individual full-length fusion transcript sequence from KinaseFusionDB, we ran ORFfinder and chose the longest ORF among the all predicted ones. |
| >Henst_Tenst_Hgene_Hchr_Hbp_Tgene_Tchr_Tbp_length(fusion AA)_AAseq |
Multiple Sequence Alignment of All Fusion Protein Isoforms |
Top |
Kinase Fusion Protein Functional Features |
| Four levels of functional features of fusion genes Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/:201729287/:201778715) - FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels. - How to search 1. Put your fusion gene symbol. 2. Press the tab key until there will be shown the breakpoint information filled. 4. Go down and press 'Search' tab twice. 4. Go down to have the hyperlink of the search result. 5. Click the hyperlink. 6. See the FGviewer result for your fusion gene. |
 |
| Main function of each fusion partner protein. (from UniProt) |
| Hgene | Tgene |
| CLK1 | ORC2 |
| FUNCTION: Dual specificity kinase acting on both serine/threonine and tyrosine-containing substrates. Phosphorylates serine- and arginine-rich (SR) proteins of the spliceosomal complex and may be a constituent of a network of regulatory mechanisms that enable SR proteins to control RNA splicing. Phosphorylates: SRSF1, SRSF3 and PTPN1 (PubMed:10480872, PubMed:19168442). Regulates the alternative splicing of tissue factor (F3) pre-mRNA in endothelial cells (PubMed:19168442). {ECO:0000269|PubMed:10480872, ECO:0000269|PubMed:19168442}. | FUNCTION: Mitochondrial transporter of the positively charged amino acids ornithine, lysine and arginine, and the neutral amino acid citrulline (PubMed:12807890). In addition, transports the basic amino acids histidine, homoarginine, and asymmetric dimethylarginine (aDMA), but not symmetric DMA, and the D-forms of lysine, arginine, ornithine and histidine (PubMed:26403849, PubMed:12807890). Functions by both counter-exchange and uniport mechanisms (PubMed:26403849). {ECO:0000269|PubMed:12807890, ECO:0000269|PubMed:26403849}. |
| Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at * Minus value of BPloci means that the break pointn is located before the CDS. |
| - Retained domain in the 5'-partner of fusion protein (protein functional feature from UniProt). |
| Partner | Hgeneene | Hbp | Tgeneene | Tbp | ENST | BPexon | TotalExon | Protein feature loci | BPloci | TotalLen | Feature | Note |
| - Retained domain in the 3'-partner of fusion protein (protein functional feature from UniProt). |
| Partner | Hgeneene | Hbp | Tgeneene | Tbp | ENST | BPexon | TotalExon | Protein feature loci | BPloci | TotalLen | Feature | Note |
Top |
Kinase-Substrate Information of CLK1_ORC2 |
| Phosphorylation target of the kinase (phosphosite, 03-17-2024) |
| Kinase | Kinase UniProt Acc | Kinase species | Substrate | Substrate UniProt Acc | Substrate phosphorylated residues | Substrate phosphorylated sites (+/-7AA) | Domain |
| CLK1 | P49759 | human | ABL1 | P00519 | T735 | DTEWRSVtLPRDLQS | |
| CLK1 | P49759 | human | RBM17 | Q96I25 | S222 | EEQDRPRsPtGPsNs | |
| CLK1 | P49759 | human | RBM17 | Q96I25 | S288 | DATEkDAsKKsDsNP | |
| CLK1 | P49759 | human | PTPN1 | P18031 | S243 | DKRkDPssVDIkKVL | Y_phosphatase |
| CLK1 | P49759 | human | SNRNP70 | P08621 | S226 | yDERPGPsPLPHRDR | |
| CLK1 | P49759 | human | RBM17 | Q96I25 | S204 | DsRPRsQsSKAAIPP | |
| CLK1 | P49759 | human | RBM17 | Q96I25 | S62 | IDLkRGGsSDDrQIV | |
| CLK1 | P49759 | human | PTPN1 | P18031 | S50 | RNRyRDVsPFDHsRI | Y_phosphatase |
| CLK1 | P49759 | human | RBM17 | Q96I25 | S202 | EEDsRPRsQsSKAAI | |
| CLK1 | P49759 | human | RBM17 | Q96I25 | S266 | QGLSTALsVEKTSKr | G-patch |
| CLK1 | P49759 | human | RBM17 | Q96I25 | S291 | EkDAsKKsDsNPLTE | |
| CLK1 | P49759 | human | RBM17 | Q96I25 | S48 | kSQRTkQsTVLAPVI | |
| CLK1 | P49759 | human | PTPN1 | P18031 | S242 | MDKRkDPssVDIkKV | Y_phosphatase |
| CLK1 | P49759 | human | NR5A1 | Q13285 | S203 | EYPEPYAsPPQPGLP |
| Biological Network Integration of This Kinase and Substrates (GeneMANIA website) |
| Enriched GO biological processes of the phosphorylation target genes of the kinase |
| Kinase | GOID | GO term | P.adjust |
| CLK1 | ID | Description | 0.00e+00 |
| CLK1 | GO:0035791 | platelet-derived growth factor receptor-beta signaling pathway | 2.87e-03 |
| CLK1 | GO:0048008 | platelet-derived growth factor receptor signaling pathway | 2.60e-02 |
| CLK1 | GO:0070373 | negative regulation of ERK1 and ERK2 cascade | 3.06e-02 |
| CLK1 | GO:0071901 | negative regulation of protein serine/threonine kinase activity | 3.87e-02 |
| CLK1 | GO:0090288 | negative regulation of cellular response to growth factor stimulus | 4.14e-02 |
| CLK1 | GO:0050731 | positive regulation of peptidyl-tyrosine phosphorylation | 4.14e-02 |
| CLK1 | GO:0043409 | negative regulation of MAPK cascade | 4.14e-02 |
| CLK1 | GO:0006469 | negative regulation of protein kinase activity | 4.14e-02 |
| CLK1 | GO:0033673 | negative regulation of kinase activity | 4.14e-02 |
| CLK1 | GO:0051348 | negative regulation of transferase activity | 4.14e-02 |
| CLK1 | GO:0050730 | regulation of peptidyl-tyrosine phosphorylation | 4.14e-02 |
| CLK1 | GO:0051651 | maintenance of location in cell | 4.14e-02 |
| CLK1 | GO:0034976 | response to endoplasmic reticulum stress | 4.14e-02 |
| CLK1 | GO:0018108 | peptidyl-tyrosine phosphorylation | 4.14e-02 |
| CLK1 | GO:0018212 | peptidyl-tyrosine modification | 4.14e-02 |
| CLK1 | GO:0045860 | positive regulation of protein kinase activity | 4.14e-02 |
| CLK1 | GO:0071900 | regulation of protein serine/threonine kinase activity | 4.14e-02 |
| CLK1 | GO:0030100 | regulation of endocytosis | 4.14e-02 |
| CLK1 | GO:0001933 | negative regulation of protein phosphorylation | 4.14e-02 |
| CLK1 | GO:0060397 | growth hormone receptor signaling pathway via JAK-STAT | 4.14e-02 |
| CLK1 | GO:0070372 | regulation of ERK1 and ERK2 cascade | 4.14e-02 |
| CLK1 | GO:0097193 | intrinsic apoptotic signaling pathway | 4.14e-02 |
| CLK1 | GO:0042326 | negative regulation of phosphorylation | 4.14e-02 |
| CLK1 | GO:0033327 | Leydig cell differentiation | 4.14e-02 |
| CLK1 | GO:0060020 | Bergmann glial cell differentiation | 4.14e-02 |
| CLK1 | GO:1903897 | regulation of PERK-mediated unfolded protein response | 4.14e-02 |
| CLK1 | GO:2000644 | regulation of receptor catabolic process | 4.14e-02 |
| CLK1 | GO:0000377 | RNA splicin | 2.98e-03 |
| CLK1 | GO:0033674 | positive regulation of kinase activity | 4.14e-02 |
| CLK1 | GO:0001553 | luteinization | 4.14e-02 |
| CLK1 | GO:0002327 | immature B cell differentiation | 4.14e-02 |
| CLK1 | GO:0030948 | negative regulation of vascular endothelial growth factor receptor signaling pathway | 4.14e-02 |
| CLK1 | GO:0048012 | hepatocyte growth factor receptor signaling pathway | 4.14e-02 |
| CLK1 | GO:0051235 | maintenance of location | 4.14e-02 |
| CLK1 | GO:0010506 | regulation of autophagy | 4.14e-02 |
| CLK1 | GO:0090287 | regulation of cellular response to growth factor stimulus | 4.14e-02 |
| CLK1 | GO:0033690 | positive regulation of osteoblast proliferation | 4.14e-02 |
| CLK1 | GO:1900103 | positive regulation of endoplasmic reticulum unfolded protein response | 4.14e-02 |
| CLK1 | GO:1900272 | negative regulation of long-term synaptic potentiation | 4.14e-02 |
| CLK1 | GO:1905244 | regulation of modification of synaptic structure | 4.14e-02 |
| CLK1 | GO:1905939 | regulation of gonad development | 4.14e-02 |
| CLK1 | GO:0030238 | male sex determination | 4.14e-02 |
| CLK1 | GO:0071871 | response to epinephrine | 4.14e-02 |
| CLK1 | GO:1903894 | regulation of IRE1-mediated unfolded protein response | 4.14e-02 |
| CLK1 | GO:0045936 | negative regulation of phosphate metabolic process | 4.14e-02 |
| CLK1 | GO:0010563 | negative regulation of phosphorus metabolic process | 4.14e-02 |
| CLK1 | GO:0001768 | establishment of T cell polarity | 4.14e-02 |
| CLK1 | GO:0051444 | negative regulation of ubiquitin-protein transferase activity | 4.14e-02 |
| CLK1 | GO:0061684 | chaperone-mediated autophagy | 4.14e-02 |
Top |
Related Drugs to CLK1_ORC2 |
| Drugs used for this fusion-positive patient. (Manual curation of PubMed, 04-30-2022 + MyCancerGenome) |
| Hgene | Tgene | Drug | Source | PMID |
| Distribution of the number of studies mentioning CLK1-ORC2 and kinase inhibitors the PubMed Abstract (04-01-2024) |
| Fusion gene - drug pair 1 | Fusion gene - drug pair 2 | PMID | Publication date | DOI | Study title |
Top |
Related Diseases to CLK1_ORC2 |
| Diseases that have this fusion gene. (Manual curation of PubMed, 04-30-2022 + MyCancerGenome) |
| Hgene | Tgene | Disease | Source | PMID |
| Related diseases from the literature mentioned this fusion gene and drug. (PubMed, 04-01-2024) |
| MeSH ID | MeSH term |
| Diseases associated with fusion partners. (DisGeNet 4.0) |
| Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
Top |
Clinical Trials of the Found Drugs/Small Molecules |
| Statistics of the Clinical Trials of the Found Kinase Inibitors from clinicaltrials.gov (06-17-2024) |
| Clinical Trials from clinicaltrials.gov (06-17-2024) |
| Fusion Gene | Kinase Inhibitor | NCT ID | Study Status | Phases | Disease | # Enrolment | Date |
Copyright 2024-Present -The University of Texas Health Science Center at Houston
Web File Viewing | Emergency Information |Campus Carry|Site Policies |